Bleeding Disorders Treatment Market Size, Share Analysis 2022–2030

Blood clotting is a mechanism that is activated when an injury results in bleeding inside or outside of the body. The clotting factors and certain plasma proteins are mainly responsible for the blood clotting mechanism. Blood disorders is a condition that involves malfunctioning of the clotting factors and plasma proteins, where blood clotting mechanism either occurs slowly or doesn’t occur at all.

According to the U.S. Centers for Disease Control and Prevention study, about 1 in 5000 people suffer from hemophilia. According to the WHO (World Health Organization), about 3.2 million of the U.S. population suffers from Von Willebrand disease and more than 14,600 women, men, and children were treated for the same at various hemophilia treatment centers between 2012 and 2016.

The increase in the prevalence of bleeding disorders among the population is likely to fuel the growth of the global bleeding disorder treatment market over the estimated timeframe. The growing awareness about the treatment of blood disorders, improvement in the technology for treating these disorders, and growing R&D activities for the development of recombinant factors are other factors projected to drive the global bleeding disorder treatment market in the future. However, the availability of counterfeit treatments and limited reimbursement policies may hinder the bleeding disorder treatment market on a global scale.

The global bleeding disorder treatment market is divided on the basis of type, drug class, and region. By type, the market for bleeding disorder treatment is segmented into hemophilia B, hemophilia A, Von Willebrand disease, and others. The growing prevalence rate of hemophilia A is anticipated to fuel the hemophilia A segment in the global bleeding disorder treatment market.

On the basis of drug class, the bleeding disorder treatment market is sectored into plasma-derived coagulation factor concentrates, desmopressin, fibrin sealants, antifibrinolytic, recombinant coagulation factor concentrates, and others. Recombinant coagulation factor concentrates held the maximum share of the blood disorder treatment market globally in 2018. The plasma-derived coagulation factor concentrates segment is expected to show a decline in the growth in the future, due to the risk to acquire blood-related infections.

By region, North America is projected to dominate the global market for blood disorder treatment in the future. This can be attributed to the rising prevalence of hemophilia A, the presence of major players in the region, and increasing population opting for prophylaxis treatment for blood diseases. Asia Pacific is expected to show the highest CAGR in the upcoming years due to the increase in the awareness about blood-related disorders, introduction of government initiatives for the treatment of blood-related disorders, and rapidly developing healthcare infrastructure.

Global Bleeding Disorder Treatment Market Key players:

• Bayer AG
• CSL Behring
• Novo Nordisk
• Pfizer Inc.
• Shire PLC
• Grifols SA
• Octapharma
• Amgen Inc.
• Cangene Corporation
• Alnylam Pharmaceuticals.

This report segments the global bleeding disorder treatment market as follows:

Global Bleeding Disorder Treatment Market: Type Analysis

• Hemophilia A
• Hemophilia B
• Von Willebrand Disease
• Others

Global Bleeding Disorder Treatment Market: Drug Class Analysis

• Plasma-Derived Coagulation Factor Concentrates
• Recombinant Coagulation Factor Concentrates
• Desmopressin
• Antifibrinolytic
• Fibrin Sealants
• Others

Global Bleeding Disorder Treatment Market: Regional Analysis

• North America
  • The U.S.
• Europe
  • UK
  • France
  • Germany
• Asia Pacific
  • China
  • Japan
  • India
• Latin America
  • Brazil
• Middle East and Africa